All In MedTech

FDA Clearance Tracker · P050052-S162

RADIESSE® Injectable Implant

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 31, 2026

Approved

Time to decision

678 days

Received May 22, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P050052-S162
Device name
RADIESSE® Injectable Implant
Applicant location
Franksville, WI
Received
May 22, 2024
Decided
Mar 31, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P050052

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications of Radiesse Injectable Implant diluted 1:2 with 0.9% sterile saline solution for subdermal implantation for the correction of décolleté wrinkles in patients 22 years of age and older.

Source documents

Other decisions for Merz North America, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.